Apyx Medical Corporation Announces Peer-Reviewed Clinical Publication Comparing the Use of Renuvion to a Competing Technology Following Liposuction or Body Contouring Procedures
09 August 2024 - 6:10AM
Business Wire
Demonstrates a statistically significant
reduction in adverse events associated with the use of Renuvion
following liposuction or body contouring, compared to the
competing technology
Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical”;
the “Company”), the manufacturer of a proprietary helium plasma and
radiofrequency platform technology marketed and sold as Renuvion®,
today announced the publication of a peer-reviewed article in the
journal, Plastic and Reconstructive Surgery—Global Open, featuring
the results of study which compared the use of Renuvion’s Helium
Plasma Technology to InMode’s Bipolar RF System (“Bipolar RF”)
following liposuction or body contouring procedures.
In this retrospective, single-center, contiguous series study,
researchers Michael Kluska, DO et al. collected demographic,
procedure and safety data from more than 450 patients who underwent
treatment with either Renuvion (n=229) or Bipolar RF (n=236)
following liposuction or body contouring procedures. The
demographic characteristics of both groups exhibited similarity in
terms of age, sex, BMI and tobacco usage.
The researchers analyzed adverse events documented during and
post-procedure by body area for both groups. Based on this
analysis, they found that the group treated with Renuvion exhibited
statistically significant fewer adverse events (p-value
<0.0001), compared to the group treated with Bipolar RF.
Specifically, 45 adverse events were documented in 34 of the
patients treated with Renuvion, compared to 93 adverse events
documented in 62 of the patients treated with Bipolar RF. 28
adverse events documented in the Renuvion group were determined to
be procedure-related, compared to 69 events in the Bipolar RF
group. The researchers found the significantly fewer occurrences of
burns, hematoma, hypertrophic scar, and seroma in the Renuvion
group to be particularly noteworthy.
Based on these findings, the researchers concluded that Renuvion
may offer a safer alternative to Bipolar RF following liposuction
or body contouring procedures. They observed that the study’s
findings underscore the importance of carefully selecting the
appropriate energy-based technology for managing skin laxity
following liposuction or body contouring procedures, and added that
Renuvion emerges as a promising option over Bipolar RF due to its
superior safety profile, shorter procedural times and higher
patient satisfaction rates compared to Bipolar RF.
“We are pleased to see the results of this important clinical
study published in a peer-reviewed, open access journal, following
its presentation at the American Academy of Cosmetic Surgery
Scientific Meeting earlier this year,” said Charlie Goodwin,
President and Chief Executive Officer. “Its findings support the
enhanced safety outcomes that can be achieved when using Renuvion
to treat loose skin following liposuction or body contouring
procedures, as compared to a commonly-used competing technology.
Apyx Medical remains committed to bringing innovative,
evidence-based medicine to surgeons and patients in the global
cosmetic surgery market, and we believe the study represents an
important addition to the extensive body of clinical evidence
supporting the safety and efficacy of our Renuvion technology.”
A digital version of the clinical publication is available via
the following link: Plastic and Reconstructive Surgery – Global
Open (lww.com)
About Apyx Medical
Corporation:
Apyx Medical Corporation is an advanced energy technology
company with a passion for elevating people’s lives through
innovative products, including its Helium Plasma Platform
Technology products marketed and sold as Renuvion in the cosmetic
surgery market and J-Plasma® in the hospital surgical market.
Renuvion and J-Plasma offer surgeons a unique ability to provide
controlled heat to tissue to achieve their desired results. The
effectiveness of Renuvion and J-Plasma are supported by more than
90 clinical documents. The Company also leverages its deep
expertise and decades of experience in unique waveforms through OEM
agreements with other medical device manufacturers. For further
information about the Company and its products, please refer to the
Apyx Medical Corporation website www.ApyxMedical.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240808954609/en/
Investor Relations:
ICR Westwicke on behalf of Apyx Medical Corporation Mike
Piccinino, CFA investor.relations@apyxmedical.com
Apyx Medical (NASDAQ:APYX)
Historical Stock Chart
From Oct 2024 to Oct 2024
Apyx Medical (NASDAQ:APYX)
Historical Stock Chart
From Oct 2023 to Oct 2024